Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for preventing or treating graft-versus-host disease comprising tlr5 agonist derived from flagellin as effective component

A graft-versus-host, flagellin technology, applied in medical preparations containing active ingredients, peptide/protein components, drug combinations, etc., can solve the problem of reducing the incidence of anti-host disease, increasing the recurrence rate of leukemia, and weakening the anti-tumor effect. and other problems, to achieve the effect of excellent therapeutic effect

Pending Publication Date: 2022-01-28
ザカソリックユニバーシティーオブコリアインダストリーアカデミックコーポレーションファウンデーション
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

On the other hand, the higher the degree of host immunosuppression, the greater the possibility of graft-versus-host disease, which is closely related to the graft-versus-tumor (GVT) effect. After increasing the intensity of immunosuppression, the incidence of graft-versus-host disease decreases, but the graft-versus-tumor effect also weakens, thus ultimately increasing the relapse rate of leukemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for preventing or treating graft-versus-host disease comprising tlr5 agonist derived from flagellin as effective component
  • Composition for preventing or treating graft-versus-host disease comprising tlr5 agonist derived from flagellin as effective component
  • Composition for preventing or treating graft-versus-host disease comprising tlr5 agonist derived from flagellin as effective component

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0052] experimental method

[0053] 1. Establish mouse model

[0054] (1) Graft-versus-host disease mouse model

[0055] Using 6-8 week old C57BL / 6(H-2kb) and BALB / c(H-2kd) mice of different MHC classes, 800cGy whole body irradiation to recipient mice BALB / c(H-2kd) Radiation of donor mice C57BL / 6 (H-2kb) bone marrow cells (5×10 6 cells) and splenocytes (5×10 6 cells) and implanted into the veins of allogeneic recipient mice to induce an animal model of graft-versus-host disease. Then, according to the clinical evaluation criteria of graft-versus-host disease (refer to Table 1 below), the mice with graft-versus-host disease were observed and evaluated twice a week, and the total score of the above-mentioned clinical evaluation criteria of graft-versus-host disease was set to 10 Among them, body weight, posture, activity, hair condition and skin density each accounted for 2 points. Table 1 below describes the clinical evaluation criteria for body weight, posture, activity, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a composition for preventing or treating graft-versus-host disease (GVHD), comprising a TLR5 agonist derived from flagellin as an effective component. The TLR5 agonist derived from flagellin of the present invention exhibits an excellent therapeutic effect on GVHD, and thus may be developed as an active ingredient of a composition for the treatment, prevention, or alleviation of GVHD.

Description

technical field [0001] The present invention relates to a composition for preventing or treating graft-versus-host disease comprising a TLR5 agonist derived from flagellin as an active ingredient. Background technique [0002] TLR5 (Toll-like receptor 5 (Toll-like receptor 5)) is a protein encoded by the human TLR5 gene (PNAS.95 (2): 588–93), which is the )) a member of the family. It is well known that TLR5 can recognize flagellin of invading motile bacteria (Seminars in Immunopathology. 29(3):275–88). TLR5 is known to be involved in the occurrence of various diseases including inflammatory bowel disease (Journal of Physiology and Pharmacology. 60 Suppl 4: 71-5). [0003] Flagellin is the major structural protein that constitutes bacterial flagellar filaments, which are small organs of motile cells. Tens of thousands of flagellin molecules are helically aggregated to form long flagellar filaments. Flagellin includes a D0 domain (domain), a D1 domain, a D2 domain and a D...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P37/06A23L33/195
CPCA23L33/195A61P37/06A61K38/164A23V2002/00A23V2200/324
Inventor 赵锡九林健一金娜延全英雨南映先宋仑珍李俊锡
Owner ザカソリックユニバーシティーオブコリアインダストリーアカデミックコーポレーションファウンデーション
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com